Objective-To compare the ability of dobutamine and dipyridamole stress echocardiography to detect functional recovery of stunned but viable myocardial regions early after acute myocardial infarction, and to predict late functional recovery of the reperfusion salvaged myocardium within the infarct area. Methods-Within 10 d of acute myocardial infarction, 51 patients-30 anterior and 21 inferior, 44 Q wave and seven non-Q-wave infarction-were submitted to a dobutamine echocardiography test at low dose (5-10 jug/kg/min over 5 min) and high dose (20-40 uglkglmin over 3 min) and to dipyridamole echocardiography test (0.56 mg/kg over 4 min + 0*28 mg/kg over 2 min) on different days and in random order, after interruption of any vasoactive drug. Resting echocardiography was repeated at two months in 41 of 51 patients (80%). Regional wall motion of the left ventricle was analysed in a semiquantitative manner on a 14-segment model. Viability was defined as improvement of one grade or more of at least two basally asynergic segments in the infarcted area. Results-Regional functional recovery was detected by low dose dobutamine in 38/51 patients (75%) and in 147/308 (48%) of basally asynergic segments, compared to 25/51 patients (49%; P < 0-001) and 78/308 segments (25%; P < 0-001) only identified by dipyridamole. Late spontaneous functional recovery was detected in 24/41 patients (59%) and in 78/254 basally asynergic segments (31%). The sensitivity of dobutamine and dipyridamole echocardiography for predicting spontaneous functional recovery was 72% and 51% respectively (P < 0.001), specificity 68% and 82% (P < 0.001), positive predictive value 50% and 56%, and negative predictive value 85% and 79%. Conclusions-In comparison with dipyridamole in patients with thrombolysed myocardial infarction, dobutamine induces regional functional recovery. This suggests that dobutamine is more sensitive in showing the presence of viable myocardium within the infarct zone, though it has a lower specificity in predicting delayed spontaneous functional recovery of non-contractile but still viable areas. (Heart 1996;75:240-246) 
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(Heart 1996;75:240-246) Keywords : stress echocardiography; dobutamine; dipyridamole; myocardial infarction Thrombolytic treatment has completely changed the natural history and prognosis of patients with acute myocardial infarction. The reduction of mortality observed in several randomised trials'-4 is principally the result of a limitation of the necrotic area and the preservation of left ventricular function obtained by the early recanalisation of the infarct related coronary artery.5-7 Therefore early identification of viable myocardium within the infarct zone could represent an important step in the prognostic evaluation and treatment of patients after myocardial infarction. Several studies have shown that after successful reperfusion of the ischaemic area the complete recovery of regional function can require a time period varying from few days to some months.8-'0 Recent studies have shown that postischaemic dysfunction can be reversed either by direct inotropic stimulation with catecholamines infusion,1' 12 or by an increase in contractility mediated by an intense pharmacological vasodilatation of coronary bed."3 On the basis of these experimental findings, low dose dobutamine and dipyridamole infusion combined with cross sectional echocardiography has been recently proposed for detection of non-contractile but viable areas after acute myocardial infarction.'4-'8 To date, however, no study has directly compared the accuracy of dobutamine and dipyridamole in identifying stunned but still viable myocardium in the infarct zone.
We therefore evaluated the ability of dobutamine and dipyridamole echocardiography to detect functional recovery suggesting the presence of myocardial viability within the infarct area in a population of patients with acute myocardial infarction treated with thrombolytic drugs. The acute response to both tests was correlated with late spontaneous functional recovery in the infarct area in order to assess whether dobutamine and dipyridamole echocardiography performed early after acute myocardial infarction could predict the improvement in wall motion abnormalities during the follow up.
Methods

POPULATION
From a population of 132 patients consecutively admitted (from January 1993 to March 1994) with a first acute myocardial infarction, diagnosed on the basis of typical chest pain lasting > 30 min, increase in creatine kinase to at least twice the normal level, and > 1 mm evolutionary S-T elevation in at least two contiguous leads, 68 patients fulfilling the following criteria were initially selected for the study: (1) age < 70 years, (2) treatment with thrombolytic drugs within 6 h from onset of chest pain, (3) no major in hospital complication, (4) no severe life limiting systemic disease, and (5) a good echocardiographic window under basal conditions. The reasons for the exclusion from the study were: age> 70 years (25 patients) , no thrombolytic treatment due to contraindication or late arrival in hospital (14 patients), major in hospital complication or death (15 patients), severe systemic disease (two patients), presence of a permanent pacemaker (two patients), or poor echocardiographic window under basal conditions (six patients). Seventeen patients who had a good echocardiographic window at baseline but showed a significant deterioration of images during dobutamine stress precluding a correct analysis of stress induced changes in wall motion, or in whom the same echocardiographic views were not available during both tests, were subsequently excluded. Therefore the final population of the study was 51 patients. Dobutamine was infused starting with an initial dose of 5 ug/kg/min for 5 min followed by a second dose of 10 ,ug/kg/min over 5 min for detection of functional recovery in the infarct area (low dose dobutamine). In all patients, both the 5 and 10 ,ug doses were examined for detection of improvement in regional function suggesting the presence of residual viable myocardium. Dobutamine infusion was then increased with incremental steps of 10 ,ug/kg/min every 3 min (high dose dobutamine) up to a maximum dose of 40 ,ug/kg/min in order to assess the presence of residual ischaemia. The first eight patients of our population underwent low dose dobutamine only, because at that time insufficient data were available about the safety of high dose dobutamine performed early after acute myocardial infarction.
DIPYRIDAMOLE ECHOCARDIOGRAPHY
Dipyridamole was given with a first dose of 0 54 mg/kg over 4 min, followed, in absence of an ischaemic response after 4 min, by an additional dose of 0-28 mg/kg over 2 min.
During the tests a 12-lead electrocardiogram recording was taken every minute and blood pressure was measured in basal conditions, and at the end of each step by cuff method. Cross sectional echocardiography was performed using a commercially available phased array imaging system (HewlettPackard model 77020 or Sonos 1000). Five standard views of the left ventricle (parastemal long axis and short axis views, apical four-and five-chamber and two-chamber views) were recorded, when possible, at baseline and during drug infusion. A test was prematurely interrupted when systolic arterial hypertension (> 220 mm Hg) or hypotension (defined as a decrease > 20 mm Hg compared to the previous step), S-T segment elevation or depression > 2 mm compared to basal, severe angina, major ventricular arrhythmias, or any other untolerated side effect developed.
ECHOCARDIOGRAPHIC ANALYSIS
Cross sectional echocardiograms were recorded on videotape and analysed off line by two independent observers blinded to the clinical and angiographic data of the patients. In case of disagreement a consensus was reached. A 14-segment model of the left ventricle was used for the analysis of regional wall motion."9 Regional wall motion analysis was performed in a semiquantitative manner and each segment was scored as follows: 1 = normal wall motion and systolic thickening; 2 = hypokinesia (marked reduction in endocardial motion and systolic thickening); 3 = akinesia (virtual absence of inward motion and systolic thickening); 4 = dyskinesia (paradoxical wall motion away from the centre of the left ventricular in systole, or systolic thickening, or both). In order to correlate the regional wall motion abnormalities with the site of coronary lesions, we also defined the territory and segments perfused by the three major coronary vessels according to a previously described scheme.'7 An asynergy wall motion score index defined as the sum of the scores assigned to each segment divided by the number of segments visualised was calculated in basal conditions, after low dose and high dose dobutamine, and after the first or second dose of dipyridamole. Functional recovery of the infarct area suggesting the presence of residual myocardial viability was considered to be significant when an improvement of contractility of one grade or more appeared in at least two basally hypokinetic or akinetic segments during low dose dobutamine infusion, or after the first or second dose of dipyridamole. Improvement of one segment was considered indicative of myocardial viability in patients showing only two basally abnormal segments. To avoid the possible influence of the tethering effect on the interpretation of dobutamine or dipyridamole induced changes in the functional border zone, improvement in contraction extending for less than 1 cm at the boundary of the infarct zone was not considered indicative of improved function in the ischaemic area.'5 The presence of residual ischaemia within the infarcted area was diagnosed when, during high dose dobutamine or after dipyridamole infusion, we observed: (1) a deterioration of contractility of basally hypokinetic segments, (2) Dobutamine and dipyridamole stress tests had concordant results for detection of regional functional recovery in 34/51 patients (67%), and 227/308 segments (74%) respectively; discordant results were observed in 17 patients (33%) and 81 segments (26%). The number of patients and segments showing functional recovery with low dose dobutamine was significantly higher compared to that obtained with dipyridamole infusion (75% v 49%, P < 0 001 and 47% v 25%; P < 0 001).
SIDE EFFECTS
Dobutamine echocardiography was prematurely interrupted in one patient (2%) who developed an increase of systolic blood pressure (> 220 mm Hg). Non-limiting side effects occurred in 11 patients (22%): brief runs of slow ventricular tachycardia (< 10 consecutive beats at a rate ranging from 90 to 120 beats/min) occurred in two patients (4%), frequent premature ventricular beats in five (10%), supraventricular arrhythmias in three (6%), and hypotension occurred in one (2%). During dipyridamole testing, minor side effects such as flushing and headache occurred in eight patients (16%) and sporadic premature ventricular beats in three (6%).
CORRELATION WITH ANGIOGRAPHIC FINDINGS
Of the 38 patients showing myocardial viability with dobutamine, 37 (97%) had either a patent infarct related coronary artery or an occlusion with collaterals, while only 8/13 patients (61%) without viability had a patent infarct related artery (P < 0 001). Also, for dipyridamole the percentage of patients with patency of the infarct related vessel was significantly higher in the group with than in the group without functional improvement of the infarct zone (100% v 77%, P < 0-05) (table  2) .
A critical stenosis of the infarct related artery was detected in 83% and 80% of the patients with functional recovery and residual ischaemia in the infarct area during dobutamine and dipyridamole infusion respectively. CORRELATION '8 No study, however, has directly compared the ability of dobutamine and dipyridamole stress echocardiography to identify stunned but still viable myocardium in the infarcted zone. In our study, detection of viable myocardium either by dobutamine or dipyridamole was strictly associated with the patency of the infarct related artery or the presence of collateral circulation to the occluded artery, which were shown to be a requisite for preservation of myocardial viability in the infarcted area. '5 1821 This correlation could also explain the results of several studies showing that patency of the infarct related coronary artery is a major determinant of left ventricular function and prognosis after acute myocardial infarction.2224 Compared with dipyridamole, dobutamine detected regional functional recovery in a greater number of patients and segments. This finding can be explained by the fact that at low doses dobutamine improves myocardial contractility in the asynergic regions by a direct inotropic effect which does not significantly affect myocardial oxygen demand and consequently is not critically dependent upon an increase in coronary blood flow. On the other hand, the ability of dipyridamole to improve wall motion abnormalities by increasing regional blood flow in the infarct related artery can be significantly conditioned by the severity of residual stenosis and consequent reduction of coronary flow reserve. This hypothesis is supported by the observation that, in our population, dipyridamole echocardiography showed regional functional recovery in six out of seven patients (85%) without, but only in 20 out of 38 patients (52%) with, critical lesions of the infarct related vessel.
It has been shown that dobutamine can improve myocardial thickening of nonischaemic but asynergic myocardium adjacent to necrotic tissue, inducing a reduction of the size of the functional border zone.25 This phenomenon could determine an overestimation of the extension of non-contractile but still viable regions. To avoid such misinterpretation, in line with other experimental and clinical studies we therefore excluded from the analysis any improvement in contractility extending for less than 1 cm at the boundary of the infarct area. '5 26 CORRELATION WITH LATE SPONTANEOUS FUNCTIONAL RECOVERY Recovery of postischaemic regional dysfunction is dependent on the presence of a patent coronary artery and on the restoration of adequate perfusion of asynergic segments.'5 27 28 Pierard et all5 showed that recovery of contractility is more frequent in viable myocardial segments in which normal perfusion is detected at positron emission tomography. Picano et al also observed a significant correlation among dipyridamole detected viability, preserved perfusion of viable segments during rest thallium scintigraphy, and late functional recovery.'8 In our study, patients with residual viable myocardium identified by dobutamine or dipyridamole echocardiography showed a significant spontaneous improvement of regional wall motion abnormalities at the two months follow up. Conversely, among the patients with no residual myocardial viability in the infarct zone, the group identified by dobutamine did not show any significant functional recovery at follow up, while the group detected by dipyridamole had a reduction in mean asynergy score index. These data suggest that dipyridamole was unable to induce regional functional recovery in a significant number of patients with viable myocardium and explain its lower sensitivity (51%) compared to that of dobutamine (72%) in predicting late functional recovery. On the other hand, specificity was higher for dipyridamole echocardiography (82%) than for dobutamine echocardiography (68%). A possible explanation is that dipyridamole improves contractility of myocardial segments where there is less severe stenosis of the infarct related artery and less compromised perfusion, and which are therefore more likely to recover spontaneously.'5 The relatively low specificity of dobutamine echocardiography for predicting functional recovery can also be explained by the fact that we evaluated spontaneous functional recovery; it would be probably higher if the patients were studied after myocardial revascularisation by coronary angioplasty or bypass grafting, as observed by other investigators.'4 In our study, specificity of dipyridamole echocardiography was similar but sensitivity lower than that obtained by Picano et all8; however, their patients were studied after a mean of 3-5 months from the acute phase of myocardial infarction and the follow up period was also longer than in our population.
SIGNIFICANCE OF DETECTION OF RESIDUAL MYOCARDIAL ISCHAEMIA
In the population studied, detection of myocardial viability was frequently associated with residual ischaemia in the infarct area identified by a deterioration of contractility following a transitory improvement of wall motion abnormalities during dobutamine or dipyridamole infusion. Dobutamine echocardiography detected residual ischaemia in the viable regions in a larger number of patients than dipyridamole echocardiography; however, the demonstration of ischaemia was highly predictive of the presence of an angiographically critical stenosis of the infarct related vessel with both tests. Patients showing this pattern of response had a less frequent functional recovery at follow up than those with viability and no residual ischaemia. It is possible to hypothesise that the presence of a critical stenosis of the infarct related coronary artery may induce a chronic hypoperfusion or recurrent episodes of ischaemia that limit or even impede spontaneous improvement of viable but non-contractile regions. [28] [29] [30] Likewise it is possible that this condition may be corrected by successful recanalisation of the infarct related vessel by coronary angioplasty or bypass grafting. '4 18 STUDY LIMITATIONS A limitation of the study may be the selection criteria of the patient population. The results we obtained in this group of patients with a first, uncomplicated myocardial infarction treated with thrombolysis cannot be extended to the general population of patients with myocardial infarction. It is likely that the prevalence of myocardial viability and ischaemia detected by dobutamine and dipyridamole would be different in a higher risk population of patients with non-thrombolysed or complicated myocardial infarction, reinfarction, or a high prevalence of multivessel coronary artery disease. Another limitation could be that our two-month echocardiographic follow up cannot be considered sufficient to fully estimate the extent of spontaneous delayed functional recovery. In fact, Galli et al recently showed that a significant improvement of perfusion and function in the infarcted area may occur as late as seven months after the acute phase.30 Thus the reported sensitivity and specificity for predicting spontaneous functional recovery would be probably different if evaluated during a longer follow up period.
CLINICAL IMPLICATIONS
In patients with recent myocardial infarction treated with thrombolytic drugs, detection of regional functional recovery within the infarct area by stress echocardiography is well correlated with patency of the infarct related coronary artery and late spontaneous functional recovery. Compared with dipyridamole, dobutamine echocardiography identifies functional recovery, suggesting the presence of myocardial viability in a greater number of patients, and shows a higher sensitivity but a lower specificity in predicting spontaneous functional recovery of the infarct area. The clinical usefulness of early identification of myocardial viability with stress echocardiography is not well established and further studies are needed to assess its prognostic significance on the long term evolution of left ventricular function. The clinical importance of early detection of viable myocardium by stress echocardiography is mainly related to the fact that viability in the infarct zone is frequently associated with residual myocardial ischaemia caused by the presence of a critical coronary stenosis, which may prevent spontaneous contractile recovery. As for viability identification, dobutamine echocardiography detects residual ischaemia in the infarct area more frequently than dipyridamole echocardiography and therefore seem to be superior in identifying viable but jeopardised myocardial regions. Further studies are needed to assess whether this difference may have clinical significance in predicting recurrent ischaemic events and functional improvement of the infarct area after revascularisation procedures. 
